rEduction of oXygen After Cardiac arresT: a Pilot Study

Overview

This Phase 2 study aims to determine the feasibility of paramedic titration of oxygen delivery in adult patients who have been resuscitated from OHCA.

Full Title of Study: “rEduction of oXygen After Cardiac arresT (EXACT): a Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2017

Detailed Description

This Phase 2 study aims to test whether paramedic titration of oxygen is feasible and results in an equivalent number of patients arriving at the ED with a safe oxygen level compared with the current approach of 100% oxygen. Hypothesis: There is no difference in the proportion of OHCA patients who arrive at the emergency department with oxygen saturation greater than or equal to 90% whether they received an inspired oxygen fraction of 100% achieved by a flow rate of 10 litres per minute compared to a titrated oxygen fraction achieved by a flow rate of 2 litres per minute. This is a Phase 2, multi-centre, prospective, randomised study to be conducted in Melbourne and Adelaide. During cardiac arrest, the patient will receive the current standard of care with oxygen delivery (≥10L/min) by ETT/ SGA connected to bag/valve/ oxygen reservoir. If ROSC is achieved, all the standard post resuscitation treatments will be given as per current ambulance Clinical Practice Guidelines, except for the amount of oxygen delivered. The initial ventilation post ROSC for two minutes will be 600mL x 10L/ minute with oxygen flow rate ≥10L/min until a satisfactory pulse oximeter trace and reading is achieved. After the eligibility criteria are met, the patients will be randomised by the opening of an opaque envelope containing a computer generated allocation to either continued oxygen >10L/min or decreased ("titrated") oxygen 2L/min with a target oxygen saturation of 90-94%. Patients allocated to oxygen >10L minute ("standard care") will continue on this therapy to hospital. In the 2L/min oxygen group, the oxygen flow will be changed immediately back to >10L/min if: – The oxygen saturation falls to <90% at any time, or – Recurrent cardiac arrest occurs, or – The pulse oximeter trace fails Following any of these events, this high-flow oxygen will continue to hospital. If a patient is extubated or has a SGA removed post randomisation because of improving conscious state, then standard care will be used (i.e. face mask with oxygen ≥10L/min). For patients with ROSC in whom intubation is planned, ventilation with high-flow oxygen will continue during the intubation process and randomisation will be delayed until 2 minutes after the ETT is confirmed as correctly placed using ETCO2 and the pulse oximeter trace reads ≥95%. At ED handover, the patient will receive oxygen therapy as determined by the treating emergency medicine physician.

Interventions

  • Drug: Oxygen
    • oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir

Arms, Groups and Cohorts

  • Experimental: Oxygen reduction
    • post-ROSC oxygen reduced to 2L per minute then delivered to maintain oxygen saturation 90-94% to hospital
  • Active Comparator: Standard Care
    • post-ROSC oxygen maintained ≥10L per minute to hospital

Clinical Trial Outcome Measures

Primary Measures

  • oxygen saturation ≥90%
    • Time Frame: baseline
    • Oxygen saturation measured on arrival at hospital by paramedics

Participating in This Clinical Trial

Inclusion Criteria

  • Adults (age ≥18 years) – Out-of-hospital cardiac arrest of presumed cardiac cause – Initial cardiac rhythm ventricular fibrillation/ ventricular tachycardia ("shockable") – Unconscious (Glasgow Coma Scale <9) – In cardiac arrest on ambulance arrival – Sustained return of spontaneous circulation (>2 minutes) – Pulse oximeter trace with oxygen saturation measured at ≥95% on bag/ reservoir with oxygen set at ≥10L/min – Patient is spontaneous breathing or ventilated using bag/valve/oxygen reservoir via endotracheal tube or SGA (i.e. laryngeal mask airway) Exclusion Criteria:

  • Female who is known or suspected to be pregnant – Dependant on others for activities of daily living (i.e. facilitated care or nursing home residents) – "Not for Resuscitation" order – EMS witnessed arrests

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Monash University
  • Collaborator
    • Ambulance Victoria
  • Provider of Information About this Clinical Study
    • Principal Investigator: Professor Stephen Bernard, Professor – Monash University
  • Overall Official(s)
    • Stephen Bernard, MD, Principal Investigator, Monash University / Alfred Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.